{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MAGE-3+Peptide",
    "query": {
      "intervention": "MAGE-3 Peptide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MAGE-3+Peptide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T16:31:33.784Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01266603",
      "title": "High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "HDIL-2",
          "type": "DRUG"
        },
        {
          "name": "recMAGE-A3 + AS15",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2011-02-22",
      "completion_date": "2018-11-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-19",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266603"
    },
    {
      "nct_id": "NCT01273181",
      "title": "MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Metastatic Renal Cancer",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2010-12",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2015-10-28",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273181"
    },
    {
      "nct_id": "NCT00960752",
      "title": "Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "gp100",
          "type": "DRUG"
        },
        {
          "name": "R848 gel",
          "type": "DRUG"
        },
        {
          "name": "MAGE-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2010-05-20",
      "completion_date": "2020-07-20",
      "has_results": true,
      "last_update_posted_date": "2021-08-13",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00960752"
    },
    {
      "nct_id": "NCT01483274",
      "title": "Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-03",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01483274"
    },
    {
      "nct_id": "NCT01307618",
      "title": "Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "NA17.A2 Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant MAGE-3.1 Antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Interleukin-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MART-1 Antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-02",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-10-24",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307618"
    },
    {
      "nct_id": "NCT00002952",
      "title": "Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant MAGE-3.1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interleukin-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "1997-01",
      "completion_date": "2002-11",
      "has_results": false,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002952"
    },
    {
      "nct_id": "NCT00090493",
      "title": "Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "MAGE-A3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2004-06",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090493"
    },
    {
      "nct_id": "NCT00003792",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "flu matrix peptide p58-66",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant MAGE-3.1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Baylor Health Care System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-04",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003792"
    },
    {
      "nct_id": "NCT00515528",
      "title": "Vaccination Plus Ontak in Patients With Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "4-peptide melanoma vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ontak",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2007-04-23",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-26",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515528"
    },
    {
      "nct_id": "NCT06472245",
      "title": "Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Patients With Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "OSE2101",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "NGS HLAA2 assay",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "OSE Immunotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 363,
      "start_date": "2024-12-03",
      "completion_date": "2028-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-07T16:31:33.784Z",
      "location_count": 79,
      "location_summary": "Beverly Hills, California • Encino, California • Los Angeles, California + 56 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06472245"
    }
  ]
}